| 11 |
N-substituted-5-[(2,5-dihydroxybenzyl)amino]salicylamides as lavendustin analogs: antiproliferative activity, COMPARE analyses, mechanistic, docking, ADMET and toxicity studies |
2025 |
| 12 |
New antiproliferative 1,3,4-oxadiazole/benzimidazole derivatives: Design, synthesis, and biological evaluation as dual EGFR and BRAFV600E inhibitors |
2025 |
| 13 |
Synthesis, characterization and antimicrobial activity of new 1,2,4-triazole and pyridine derivatives bearing methyl 4-aminosalicylate moiety as a substructure |
2025 |
| 14 |
Design, Synthesis and Pro- Inflammatory Activity of Palmitoylated Derivatives of Thioglycolic Acid as New Immunomodulators |
2024 |
| 15 |
Design, synthesis, and apoptotic antiproliferative action of new 1,2,3-triazole/1,2,4-oxadiazole hybrids as dual EGFR/VEGFR-2 inhibitors. |
2024 |
| 16 |
Tetrahydrocarbazoles incorporating 5-arylidene-4-thiazolinones as potential antileukemia and antilymphoma targeting tyrosine kinase and tubulin polymerase enzymes: Design, synthesis, structural, biological and molecular docking studies |
2024 |
| 17 |
Antiviral activity of sulphated specialized metabolites from sea urchin Clypeaster humilis: in vitro and in silico studies |
2024 |
| 18 |
Benzimidazole-based derivatives as apoptotic antiproliferative agents: Design, synthesis, docking, and mechanistic studies |
2024 |
| 19 |
Bioassay-guided isolation and in Silico characterization of cytotoxic compounds from Hemimycale sp. Sponge targeting A549 lung cancer cells |
2024 |
| 20 |
Combining lavendustin C and 5-arylidenethiazolin-4-one-based pharmacophores toward multitarget anticancer hybrids |
2024 |
